Author: Newron Pharmaceuticals SpA

Newron Pharmaceuticals to Participate in H.C. Wainwright 28th Annual Global Investment Conference

September 3, 2026
Newron announces completion of screening for enrollment in pivotal Phase 3 ENIGMA-TRS 1 study with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)

September 2, 2026

Newron Pharmaceuticals to Participate in H.C. Wainwright 28th Annual Global Investment Conference